H ypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular disorder, affecting ≈1 in 500 people within the general population, 1 and is inherited in an autosomal-dominant fashion. According to the American Heart Association/American College of Cardiology guidelines, HCM is defined as left ventricular hypertrophy in the absence of any other cardiac or systemic disease (eg, hypertension, aortic stenosis, metabolic cardiomyopathy) capable of producing the magnitude of hypertrophy evident. 2 
Clinical Perspective on p 26
During the past decade, genetic testing in HCM has gained increasing attention, and >1000 unique mutations in at least 13 genes encoding sarcomere or sarcomere-related proteins have been described. [3] [4] [5] However, limitations to the clinical application of genetic testing include the lack of consistent genotype-phenotype correlations, the identification of variants of unknown significance (VUS), and incomplete knowledge of all genes associated with left ventricular hypertrophy. [6] [7] [8] [9] Currently, genetic testing is not part of routine clinical management in the majority of patients and has substantial limitations owing to a relatively low detection rate, its limited impact on the decision-making process in an individual patient, and the substantial financial burden (approximately $3000 per test panel in North America). However, it is helpful for confirmation of the diagnosis in ambiguous situations, identifies at-risk family members whenever a familial mutation is known, and identifies HCM phenocopies, which may be amenable to alternate therapies. 5, 10 Moreover, several reports suggest that genetic testing in HCM may have long-term implications in terms of cost-effectiveness by identifying family members with positive and negative genotypes, and thus reducing the number of family members requiring serial clinical follow-up. 11, 12 The cost-effectiveness is closely related to the detection rate of Background-Genotyping in hypertrophic cardiomyopathy has gained increasing attention in the past decade. Its major role is for family screening and rarely influences decision-making processes in any individual patient. It is associated with substantial costs, and cost-effectiveness can only be achieved in the presence of high-detection rates for disease-causing sarcomere protein gene mutations. Therefore, our aim was to develop a score based on clinical and echocardiographic variables that allows prediction of the probability of a positive genotype.
Methods and Results-Clinical and echocardiographic variables were collected in 471 consecutive patients undergoing genetic
testing at a tertiary referral center between July 2005 and November 2010. Logistic regression for a positive genotype was used to construct integer risk weights for each independent predictor variable. These were summed for each patient to create the Toronto hypertrophic cardiomyopathy genotype score. A positive genotype was found in 163 of 471 patients (35%). Independent predictors with associated-risk weights in parentheses were as follows: age at diagnosis 20 to 29 (−1), 30 to 39 (−2), 40 to 49 (−3), 50 to 59 (−4), 60 to 69 (−5), 70 to 79 (−6), ≥80 (−7); female sex (4); arterial hypertension (−4); positive family history for hypertrophic cardiomyopathy (6); morphology category (5); ratio of maximal wall thickness:posterior wall thickness <1.46 (0), 1.47 to 1.70 (1), 1.71 to 1.92 (2), 1.93 to 2.26 (3), ≥2.27 (4). The model had a receiver operator curve of 0.80 and HosmerLemeshow goodness-of-fit P=0. 22 . February 2013 disease-causing mutations in each HCM population, which can vary widely and ranges between 15% and 70%. [13] [14] [15] [16] On the basis of these considerations, the aim of our study was to construct a score to identify patients with a high probability of a positive HCM genotype. In the past, several factors have been shown to be associated with a positive genotype, including younger age at diagnosis, greater maximal wall thickness (MWTH), typical septal morphology, positive family history of HCM, and absence of arterial hypertension. 5, [14] [15] [16] However, no study has combined these factors to develop a prediction model that would assist in the decision making for genetic testing and its cost-effectiveness.
Methods

Patient Selection
The study subjects were identified through the database of the multidisciplinary HCM clinic at the Toronto General Hospital, which serves as a large tertiary referral center, where genetic testing is offered on a regular basis during routine clinic visits by genetic counselors specialized in cardiac genetics. Between July 2005 and November 2010, 504 unrelated probands consented to genetic testing for HCM. The clinical diagnosis of HCM was based on the 2-dimensional echocardiographic finding of unexplained left ventricular hypertrophy with a MWTH ≥13 mm. 2 Patients with concomitant arterial hypertension were required to have a ratio of septal:posterior wall thickness (PWTH) ≥1.5.
17, 18 The study was approved by the research ethics board of the University Health Network.
Genetic Testing
Genetic testing for HCM comprised a combination of commercially available panels, including oligonucleotide hybridization-based DNA sequencing and dideoxy-based DNA sequencing. Testing initiated after February 2008 assessed 8 HCM-associated myofilament-encoding genes, involving myosin-binding protein C (MYBPC3), β-myosin heavy chain (MYH7), essential and regulatory myosin light chains (MYL2, MYL3), cardiac troponin T (TNNT2), cardiac troponin I (TNNI3), α-tropomyosin (TPM1), and cardiac actin (ACTC), as well as 3 genes associated with metabolic cardiomyopathies: GLA for Fabry disease, LAMP2 for Danon disease, and PRKAG2 for PRKAG2 cardiomyopathy. Testing initiated before February 2008 did not include the GLA gene, and testing was initiated only in the setting of a clinical presentation suggestive of Fabry disease.
Gene variants detected by genetic testing that were classified as pathogenic or presumed pathogenic were considered diseasecausing (positive genotype). Variant pathogenicity was based on the interpretation provided by the laboratory that performed the genetic analysis. These determinations were derived from a combination of factors, which may have included absence in control chromosomes, presence in unrelated probands, in silico predictions, conservation across species, and segregation analysis. VUS were considered a negative genotype because of ambiguity with respect to their pathogenic role.
Clinical Data
Clinical information was obtained by means of retrospective chart review. The presence of arterial hypertension was defined as either a blood pressure >140/90 mm Hg during 2 separate clinic visits or if a patient was diagnosed and medically treated for arterial hypertension by his or her treating physician. Importantly, family history of HCM or sudden cardiac death was assessed through detailed pedigree analysis by genetic counselors. A positive family history for HCM was defined as either documented evidence of HCM in a family member (based on a review of clinical investigations or autopsy reports) or a highly convincing patient report. A positive family history for sudden cardiac death was defined as unexplained death in first-or seconddegree relatives <50 years of age. All clinical information used in this study was assessed during the patients' clinic visit for genetic testing with 2 exceptions: (1) the age reported is the age at diagnosis of HCM, and (2) New York Heart Association class was reported at initial presentation to minimize the effect of medical treatment and septal reduction therapies (surgical myectomy or septal ethanol ablation) on symptomatic status.
Echocardiography
Echocardiography was performed using commercially available ultrasound equipment during the outpatient visit at the HCM clinic according to the standards of the American Society of Echocardiography. 19 For the purpose of this study, the echocardiogram closest to the time of genetic testing was analyzed. In patients who had undergone septal reduction therapies (surgical myectomy or septal ethanol ablation), the echocardiographic images acquired before the respective intervention were analyzed. The morphological subtypes (reversed curvature, neutral septum, apical and sigmoid septum) have been previously defined by Binder et al. 15 In patients in whom the pattern of hypertrophy did not fall into one of these predefined categories (eg, hypertrophy of the lateral wall), the subtype was defined as other. Left ventricular outflow tract obstruction was defined as either a resting or provocable gradient >30 mm Hg. The studies were interpreted by a single investigator with respect to diagnosis and morphology (C.G.), with a subset of cases reviewed by a second senior investigator (H.R.). The 2-dimensional measurements were performed by a single experienced cardiac sonographer (H.Y.).
Statistical Analysis
The primary binomial marker for this study was a positive genotype for HCM. SAS 9.2 (SAS Institute, Cary, NC) and SPSS 11.5 (IBM, Armonk, NY) were used for data analysis. Bivariate analysis included unpaired t test for comparison of continuous variables and χ 2 or Fisher exact test for comparison of categorical variables, where appropriate. A probability value <0.05 was considered significant.
For the purpose of building the HCM genotype prediction score, age at diagnosis was categorized into decades starting at 20 years of age: <20, 20s, 30s, 40s, 50s, 60s, 70s, ≥80. A minimum age of 20 years was selected as a cutoff value because of manifestation of the disease most commonly in adulthood. The ratio of MWTH:PWTH was divided into quintiles providing the following categories: ≤1.46, 1.47 to 1.70, 1.71 to 1.92, 1.93 to 2.26, ≥2.27. The HCM morphological subtypes were categorized as follows: reversed curvature and neutral septum in category I; and sigmoid septum, apical, and other in category II. This approach was based on previous data demonstrating that most disease-causing sarcomere protein gene mutations were found and described in patients with a reversed curvature or neutral septum morphology, 15 whereas the detection rate for the same mutations seemed to be low in apical HCM, suggesting that mutations other than the known affected gene loci or modifiers might be more important. 8 The sigmoid morphology is usually associated with a later onset of disease, a higher proportion of patients with arterial hypertension, and a low rate of disease-causing sarcomere protein gene mutations. 15, 20 Development of the Toronto HCM Genotype Score
Long Model
Candidate variables included clinical and echocardiographic variables, which are listed in Tables 1 and 2 . In a first step, they were compared bivariately regarding their association with a positive genotype. Those variables resulting in bivariate probability values <0.10, or those previously shown to be important but failing the critical α-level and without being highly correlated with each other, were selected for submission to logistic regression analysis using stepwise selection and an α of 0.05 for model retention. Variables selected were age by decade, body mass index, left atrial volume index, quintiles of the ratio MWTH:PWTH, enddiastolic left ventricular diameter, end-systolic left ventricular diameter, female sex, history of hypertension, diabetes mellitus, hyperlipidemia, atrial fibrillation, coronary artery disease, shortness of breath, a positive family history of HCM, a positive family history of sudden cardiac death, left ventricular outflow tract obstruction, and septum morphology category I.
Risk weights for each predictor variable in the derivation HCM genotype prediction model were constructed according to previously described methods. 21 In summary, regression coefficients for each variable were divided by the absolute value of the lowest regression coefficent in the model (age: −0.1922) and then rounded to the nearest integer. The overall HCM genotype score was then calculated by summing the risk weights for each variable that characterized the patient. Score values < −6 and >15 were collapsed owing to small numbers in each level. Tertiles of the genotype score were used to produce 3 relative likelihood groups: low, intermediate, and high.
Short Model
To compare the long model with the 2 most important and widely accepted factors associated with a positive genotype, namely HCM morphological subtype and positive family history of HCM, a short model including only those 2 factors was created as a means of comparison. For both, the short and the long model, the percentage of predicted genotype+ was compared to the percentage of observed genotype+ at each integer value of the summed Toronto HCM genotype score. Model discrimination was evaluated by the area under the receiver operator characteristics (ROC) curve, with model precision evaluated by the Hosmer-Lemeshow goodness-of-fit statistic. Areas under the ROC curves were compared using Stata 10 Special Edition (StataCorp, College Station, TX).
Bootstrap validation of the components of the risk score was performed by generating 100 data sets composed of 425 randomly selected patients (90%). The logistic regression analysis using the full variable list was run in each data set. The independent predictors and their regression coefficients from each of the 100 analyses were appended into a summary data set. The means, SEs, and 95% confidence intervals were calculated for each of the parameter regression coefficients. Variables were considered important if they appeared in >80% of the models.
Results
Of the 504 probands that underwent genetic testing, 4 patients were found to have a disease-causing mutation for metabolic cardiomyopathies (2 patients with Fabry disease, 1 patient with Danon disease, and 1 patient with PRKAG2 cardiomyopathy) and were excluded from further analysis. For the remaining 500 probands, complete data sets for clinical and echocardiographic variables were available for 471 subjects. Twenty-nine patients were excluded from analysis because of a lack of echocardiographic data before septal reduction therapies. In our HCM cohort, 163 of 471 patients (35%) had a positive genotype (genotype + ). The distribution of the disease-causing sarcomere protein gene mutations is shown in Table 3 , with mutations in the MYBCP3 and MYH7 genes accounting for the majority (>80%) of the mutations found. Overall, 70 VUS were found, predominantly involving MYBPC3 (n=34) and MYH7 (n=18) genes.
Bivariate Analysis
Significant demographic, clinical, and echocardiographic variables predicting a positive genotype are shown in Tables  1 and 2 , respectively. New York Heart Association functional class, chest pain, syncope, atrial fibrillation, and coronary artery disease had no significant association with the genotype, along with left ventricular dimensions and ejection fraction.
Multivariable Analysis and Model Performance and Validation
Long Model
Overall, the following 16 candidate variables were submitted to the multivariable regression analysis: age by decades >19 years, female sex, presence of shortness of breath, arterial hypertension, dyslipidemia, diabetes mellitus, positive family history of HCM, positive family history of sudden cardiac death, left ventricular end-diastolic diameter, left ventricular end-systolic diameter, left ventricular ejection fraction, septal thickness, MWTH, ratio MWTH:PWTH, morphology category, and left ventricular outflow tract obstruction. The multivariable regression analysis resulted in 6 independent predictors for a positive genotype, listed along with their odds ratios in Table 4 . Associated integer risk weights were assigned to each independent predictor (Table  5) , which can be summed to create the Toronto HCM genotype score. The associated probability for a positive genotype for each summed HCM genotype score can be obtained from Figure 1A or can be calculated using the following formula ). Tertiles of the Toronto HCM genotype score (long model) were used to construct 3 relative risk groups ( Figure 1B ): low (genotype + probability 11%, score range, −9 to −1), intermediate (genotype + probability 30%, score range, 0-6), and high (genotype + probability 66%, score range, 7-19). Figure 1A compares predicted and observed positive genotypes for each increment in the Toronto HCM genotype score showing a good level of precision for the model reflected by a probability value of 0.22 for the Hosmer-Lemeshow goodness-of-fit Figure 1C demonstrates the correlation between the predicted and observed positive genotype. The linear regression, at the patient level, between positive genotype and the predicted probability was slightly lower than the long model but did reach statistical significance (R 2 =0.187; P<0.001). Model precision was excellent, reflected by a probability value of 0.9035 for the HosmerLemeshow goodness-of-fit statistics. Model discrimination was good (ROC area=0.744; P<0.001) but was significantly lower than the long model (Figure 2) . With the long model, an additional 40 patients (8.5% of the cohort) were correctly classified in a higher score tertile for a positive genotype than with the short model, whereas the short model correctly classified another 7 patients (1.5% of the cohort) in a higher score tertile for a positive genotype compared with the long model. This finding implies that by using the long model, 7% of patients are classified more correctly compared with the short model.
Bootstrap Validation
Online-only Data Supplement Table I contains the results of the bootstrap validation analysis in 100 randomly generated data sets. Only those variables that were present in >80% of the results were considered important independent predictors. The means of the regression coefficients of the 6 important predictors were remarkably similar to the regression coefficients in the final long model.
Discussion
In the present study, we describe a novel predictive tool to assess the probability of a positive genotype in our HCM population based on clinical and echocardiography variables. Overall, 471 HCM probands were submitted to probability modeling, representing 1 of the largest genotyped HCM cohorts assessed in the literature. This sample size allowed testing of an appropriate range of candidate variables, and the development of a score that predicts a positive HCM genotype with good levels of discrimination and precision. In the Toronto HCM genotype score, age at diagnosis, female sex, absence of arterial hypertension, positive family history of HCM, the morphological subtype, and the ratio of MWTH:PWTH were strong independent predictors of a positive genotype. These findings are in agreement with previous reports that have demonstrated a significant association among a positive genotype and younger age, greater MWTH, typical septal morphology, positive family history of HCM, and absence of arterial hypertension. 5, [14] [15] [16] However, this is the first study to use a score to predict the probability of a positive HCM genotype in any individual patient based on the above-listed variables. It has to be emphasized that our model is based on observations at the time of genetic testing, which implies that there was a wide variation in patients ranging from patients who were followed in our HCM clinic for decades to patients who were newly referred. This may seem to be a disadvantage, but it certainly reflects the current situation in many tertiary referral centers providing care for HCM patients.
With respect to the morphological subtypes in our population, there are 2 remarkable findings in our cohort: (1) we have a high proportion of apical HCM patients, and (2) the proportion of genotype+ patients with a sigmoidshaped septum is higher than previously described in other populations. 15 According to epidemiological studies, the usual prevalence of apical HCM is 3% to 10% (excluding Japan, where up to 20% of patients express the apical variant of the disease). 22, 23 This may be explained by the specialized interest in apical HCM in our center 8, 24 and a subsequent referral bias resulting in a high proportion of patients with apical HCM (17%) undergoing genetic testing. However, from a statistical point of view, this does not impair the validity of the Toronto HCM genotype score. On the contrary, the relatively evenly distributed morphological subtypes provide even numbers of observations, rendering the model more stable. Compared with Binder et al, who describe a positive genotype in 8% of their patients with a sigmoid-shaped septum, our proportion of genotype + patients is substantially higher at 22%, despite a similar prevalence of a positive family history for HCM and an even higher prevalence of arterial hypertension in our patient cohort. However, we were restrictive with the diagnosis of HCM in patients with arterial hypertension necessitating a septal:PWTH ratio ≥1.5. 17, 18 If anything, the higher proportion of genotype + patients with a sigmoid-shaped septum would weaken the model. Hence, the validity of the Toronto HCM genotype score in its current form is not limited by this finding.
Most of the variables used in the Toronto HCM genotype score are logical and have previously been reported to be predictive by other investigators. However, female sex as an independent genotype predictor is more surprising. Acknowledging that HCM is inherited in an autosomal-dominant fashion, it is noteworthy that the proportion of female patients in other cohorts is <50%, ranging from 29% to 45%. [14] [15] [16] [25] [26] [27] Underrepresentation of women in HCM populations along with usually more severe manifestation of the disease has been described previously 26, 28 and may reflect a referral bias in female HCM patients, resulting in a higher proportion of females with sarcomeric disease. The possibility of biological sex differences influencing disease penetration 29 and expression is currently not fully understood and requires further investigations.
We found that one third of patients reaching a score ≥7 had a high probability (>60%), and one third of patients reaching a score <0 had a low probability (≈10%) for a positive HCM genotype. The current yield of genetic testing in HCM populations ranges between 30% and 50%. This information is useful in predicting the probability of a positive genotype; however, the decision to recommend genetic testing depends on the resources available for testing. It may help payers to fund patients in the high-probability group. This does not preclude funding for testing the low-probability group but confirms the likelihood of a low yield and less cost-effective approach.
In situations where the long model of the Toronto HCM genotype score cannot be applied or seems to be too complicated, the short model, which includes only the HCM morphological subtype and positive family history of HCM as predictors, seems to be an acceptable alternative. Using the long model, overall 7% of the patients were more correctly classified in a higher-score tertile for a positive genotype than with the short model. Nonetheless, the short model also showed excellent correlation between the predicted and observed genotype but was slightly less robust in discrimination than the long model.
The American College of Cardiology/American Heart Association 2011 guidelines for the diagnosis and management of HCM recommend genetic testing as a level 1 indication for patients with an atypical presentation for HCM or when another genetic condition is suspected. In addition, a level 2A recommendation was that genetic testing is reasonable in the index patient to facilitate the identification of first-degree family members at risk for developing HCM. 2 Despite the evidence for these recommendations and the commercial availability of testing, only a minority of HCM patients in North America undergo clinical genetic testing and counseling. This finding is likely because <50% of patients will have a detectable diseasecausing mutation and due to the relatively high cost of testing, which is often prohibitive. The recent guidelines 2 also recommend that ECG and echocardiograms be performed every 12 to 18 months in the offspring of patients with HCM at 12 years of age or earlier, with earlier signs of growth spurt or puberty or if there are plans to engage in competitive sports. First-degree relatives over 18 years of age should be screened every 5 years or at the onset of symptoms.
Recent reports have shown that genetic testing can be costeffective by identifying family members with positive and negative genotypes, and thus reducing the number of family members who would otherwise require serial clinical monitoring. 11, 12 However, cost-effectiveness is closely related to the detection rate of disease-causing mutations in each HCM population. The Toronto HCM genotype score, both the long and short models, is a useful tool to increase the diagnostic yield of genetic testing in HCM by identifying those with a higher pretest probability of having a positive genotype. Although costeffectiveness is currently an important reason to consider using a prediction model such as this, it is well recognized that the cost of genetic testing is certain to decrease in the coming years. However, detection of VUS and interpretation of those variants are likely to remain challenges for the future. By using this tool, which in its design excludes VUS, it will help physicians and genetic counselors determine which families are truly at the highest likelihood of detecting a true disease-associated mutation while minimizing the likelihood of an ambiguous result. This approach thereby increases the inherent value of offering genetic testing because identification of at-risk family members remains its primary purpose at this time. 
Limitations
The Toronto HCM genotype score was developed and internally validated based on the data of 1 tertiary referral center and may not be interchangeably applied to other HCM populations. However, considering that the majority of the independent predictors for a positive genotype were also found to be associated with the presence of disease-causing sarcomere protein mutations in other HCM cohorts, [14] [15] [16] we believe it is highly likely that this score will translate to other patient populations. Nonetheless, external validation of the Toronto HCM genotype score in other HCM populations is required.
Although the precision and discrimination of our model was good, the model's robustness could be improved by a larger sample size.
Conclusions
In the light of the current economic constraints faced by the majority of healthcare systems, where cost-effectiveness is becoming increasingly important, we have developed a score that predicts the genotype in HCM with good precision and discrimination. The Toronto HCM genotype score is a useful tool to streamline genetic testing toward patients with a higher probability of a positive genotype to increase the diagnostic yield of genetic testing. An increased detection rate of diseasecausing sarcomere protein gene mutations, which would subsequently allow cascade screening of family members and negate the need for ongoing clinical screening in genotypenegative individuals, will ultimately prove to be cost-effective. The majority of the independent predictors in our cohort have been found to be associated with a positive genotype in other HCM cohorts as well, and therefore the use of the Toronto HCM genotype score might be transferred to other tertiary referral centers providing care for HCM patients. However, validation of the model developed in this study is required in HCM populations elsewhere.
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